Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea
Last year, Regeneron reported $2.7 billion in Eylea sales, projecting $3.2 billion for this year. And now, 5 years after the blockbuster approval that set the company up for one of the most remarkable R&D runs in biotech, the company is going to work with a new delivery technology to see if they can make a better drug, with a fresh patent runway.
This morning, Regeneron $REGN and Ocular Therapeutix $OCUL spelled out a $315 million deal to use Ocular’s “hydrogel” on Eylea, exploring its potential to more durably get the drug into the back of the eye, reducing the number of injections patients face when treated for wet, age related macular degeneration and other retinal diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.